Vaccination against COVID-19 in patients with allergy: experience of the allergological center in Dnipro
DOI:
https://doi.org/10.26641/2307-0404.2023.2.283163Keywords:
COVID-19, vaccination, anaphylaxis, hypersensitivity, anphylactogenic substances, tryptase, immunoglobulin E, bronchial asthma, urticaria, allergic rhinitis, hay fever, mastocytosis, atopic dermatitis, comorbidityAbstract
Vaccination against COVID-19 is the main global preventive measure in the fight against SARS-CoV-2. As the COVID-19 vaccine will be administered to billions of individuals worldwide during the pandemic, there exists a reasonable fear of severe adverse reactions requiring constant vigilance and careful treatment, particularly in individuals with a history of severe allergy. The aim of our study was to develop and implement an algorithm for the safe vaccination against COVID-19 in patients with pathology associated with hypersensitivity reactions. From January to June 2022, after signing the informed consent, 126 adult patients with relevant diseases in remission were included in a prospective single-center study. Complaints and case histories were collected from all patients, including comorbidity and medications received, anthropometric data were studied, a standard clinical examination was performed, tryptase in venous blood was measured, the level of control was additionally assessed in patients with asthma using the asthma control test and spirography. According to the results of the study, it was proven that vaccination against COVID-19 in patients with pathology associated with hypersensitivity reactions is safe, on condition of prior consultation with an allergist and performing vaccination in a medical institution. The algorithm developed for preparing for vaccination in the mentioned above persons consists of a careful collection of case history; assessment and, in case of absence – achieving control of the underlying disease; analysis and correction of therapy with temporary replacement of medications that are potential cofactors of anaphylaxis; determination of blood tryptase level. For safe vaccination in patients with severe allergic anamnesis, administration of 20 mg of desloratadine before each dose of the vaccine with observation after vaccination within 30 minutes is suggested.
References
Barbaud A, Garvey LH, Arcolaci A, Brockow K, Mori F, Mayorga C, et al. Allergies and COVID-19 vaccines: An ENDA/EAACI Position paper. Allergy. 2022 Aug;77(8):2292-312. doi: https://doi.org/10.1111/all.15241
Bousquet J, Agache I, Blain H, Jutel M, Ventura MT, Worm M, et al. Management of anaphylaxis due to COVID-19 vaccines in the elderly. Allergy. 2021 Oct;76(10):2952-64. doi: https://doi.org/10.1111/all.14838
Banerji A, Wickner PG, Saff R, et al. mRNA vaccines to prevent COVID‐19 disease and reported allergic reactions: current evidence and approach. J Allergy Clin Immunol Pract. 2021;9(4):1423-37. doi: https://doi.org/10.1016/j.jaip.2020.12.047
Klimek L, Jutel M, Akdis CA, et al. ARIA‐EAACI statement on severe allergic reactions to COVID‐19 vaccines – an EAACI‐ARIA position paper. Allergy. 2021;76(6):1624‐8. doi: https://doi.org/10.1111/all.14726
Shimabukuro T. COVID‐19 vaccine safety update. Advisory Committee on Immunization Practices (ACIP) January 27, 2021. National Center for Immunization and respiratory diseases CDC [Internet]. 2021 [cited 2022 Dec 10]. Available from: https://wwwcdcgov/vaccines/acip/meetings/downloads/slides‐2021‐01/06‐COVID‐Shimabukuropdf
Shimabukuro T, Nair N. Allergic reactions including anaphylaxis after receipt of the first dose of Pfizer‐BioNTech COVID‐19 vaccine. JAMA 2021;325(8):780. doi: https://doi.org/10.1001/jama.2021.0600
Klimek L, Novak N, Cabanillas B, Jutel M, Bousquet J, Akdis CA. Allergenic components of the mRNA‐1273 vaccine for COVID‐19: Possible involvement of polyethlene glycol and IgG‐mediated complement activation. Allergy. 2021 Nov;76(11):3307-13. doi: https://doi.org/10.22541/au.160952242.21038379/v1
Caminati M, Guarnieri G, Senna G. Who Is Really at Risk for Anaphylaxis Due to COVID-19 Vaccine? Vaccines. 2021;9:38. doi: https://doi.org/10.3390/vaccines9010038
Francuzik W, Dölle-Bierke S, Knop M, Scherer Hofmeier K, Cichocka-Jarosz E, García BE, et al. Refractory Anaphylaxis: Data From the European Anaphylaxis Registry. Front Immunol. 2019 Oct 18;10:2482. doi: https://doi.org/10.3389/fimmu.2019.02482
Cabanillas B, Akdis C, Novak N. Allergic reactions to the first COVID‐19 vaccine: a potential role of Polyethylene glycol? Allergy. 2021;76(6):1617‐8. doi: https://doi.org/10.1111/all.14711
Worm M, Ring J, Klimek L, Jakob T, Lange L, Treudler R, et al. Anaphylaxie-Risiko bei der COVID-19-Impfung: Empfehlungen für das praktische Management [Covid-19 vaccination and risk of anaphylaxis – Recommendations for practical management]. MMW Fortschr Med. 2021 Jan;163(1):48-51. doi: https://doi.org/10.1007/s15006-021-9530-6
Gashynova K, Suska K, Dmytrychenko V. Microbiome landscape and disease duration role in allergy in adult patients with bronchiectasis. Eur Respir J. 2019;54(63):PA2763. doi: https://doi.org/10.1183/13993003.congress-2019.PA2763
Dytyatkovska E, Gashynova K, Panov V. Patterns of molecular sensitization in adults in Dnipro region (Ukraine). Allergy. 2019;74:831-2. doi: https://doi.org/10.37219/2528-8253-2020-6-42
Perceva TA, Gashinova EYu. ["Difficult" asthma: life goes on]. Zdorovia Ukrainy. 2007;8:165. Russian.
[On the approval and implementation of medical and technological documents on the standardization of medical care for bronchial asthma. Order of the Ministry of Health of Ukraine dated October 8, 2013 No. 868]. [Internet]. 2013 [cited 2022 Aug 26]. Available from: https://zakon.rada.gov.ua/rada/show/v0868282-13#Text
Knudson RJ, Lebowitz MD, Holberg CJ, Burrows B. Changes in the normal maximal expiratory flow-volume curve with growth and aging. Am Rev Respir Dis. 1983Jan.1;127(6):725-34.
Glantz SA. Primer of biostatistics. 4th ed. New York: McGraw-Hill, Health Professions Division; 1997. 473 p.
Ring J, Beyer K, Biedermann T, et al. Guideline (S2) on acute therapy and management of anaphylaxis: 2021 update. S2- Guideline of the German Society for Allergology and Clinical Immunology (DGAKI), the Medical Association of German Allergologists (AeDA), the Society of Pediatric Allergy and Environmental Medicine (GPA), the German Academy of Allergology and Environmental Medicine (DAAU), the German Professional Association of Pediatricians (BVKJ), the Society for Neonatology Paediatric Intensive Care (GNPI), the German Society of Dermatology (DDG), the Austrian Society for Allergology and Immunology (ÖGAI), the Swiss Society for Allergy and Immunology (SGAI), the German Society of Anaesthesiology and Intensive Care Medicine (DGAI), the German Society of Pharmacology (DGP), the German Respiratory Society (DGP), the patient organization German Allergy and Asthma Association (DAAB), the German Working Group of Anaphylaxis Training and Education (AGATE). Allergo J Int. 2021;30:1-25. doi: https://doi.org/10.1007/s40629-020-00158-y
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2023 Medicni perspektivi
This work is licensed under a Creative Commons Attribution 4.0 International License.
Submitting manuscript to the journal "Medicni perspektivi" the author(s) agree with transferring copyright from the author(s) to publisher (including photos, figures, tables, etc.) editor, reproducing materials of the manuscript in the journal, Internet, translation into other languages, export and import of the issue with the author’s article, spreading without limitation of their period of validity both on the territory of Ukraine and other countries. This and other mutual duties of the author and all co-authors separately and editorial board are secured by written agreement by special form to use the article, the sample of which is presented on the site.
Author signs a written agreement and sends it to Editorial Board simultaneously with submission of the manuscript.
